Google
DHR 株価分析 — DANAHER CORPORATION (Healthcare >> Diagnostics & Research)
DHR に関するよくある質問
DHRのPER（株価収益率）は？
DANAHER CORPORATION（DHR）は現在PER 34.44倍で取引されています。
DHRのROE（自己資本利益率）は？
DANAHER CORPORATIONのROEは7.61%です。
DHRの配当利回りは？
DANAHER CORPORATIONの配当利回りは0.73%です。
DHRの品質スコア（Quality Score）は？
当社のAIはDHRの総合財務品質を100点中54点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
DHRは今が買い時ですか？
当社AIのタイミングスコアは100点中89点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
DHRはどのセクターに属しますか？
DANAHER CORPORATIONはHealthcare >> Diagnostics & Researchセクターに分類されます（NYSE市場）
DHR AI Analysis Summary
Our AI summary for DHR: DANAHER CORPORATION (NYSE), Healthcare >> Diagnostics & Research sector. The stock currently trades at a P/E of 34.44, ROE of 7.61%, a dividend yield of 0.73%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 194.98
Price
-1.19
(-0.61%)
Day Change
|
|
|---|
DHR, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
2239
|
| Magic Formula Rank by ROE |
2239
|
| Magic Formula Rank by ROIC |
2595
|
| Price | 194.98 |
| PBV / Sector |
2.62 / -29.69
|
| Earning Per Share | 5.66 |
| PE / Sector |
34.44 / 48.18
|
| PEG or PE/Growth / Sector |
-1.85 / 1.64
|
| Average 1M Daily Value |
1,161.39 M
GREAT
|
| Average 1W Daily Value |
1,099.64 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
54% |
| ポイントになる統計 |
|
64% |
| 配当 |
|
41% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:43 |
| Symbol | DHR |
| Name | DANAHER CORPORATION |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NYSE |
| Listed Shares | 702.99 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 137,904.77 / 38,081.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2200 Pennsylvania Avenue N.W., Washington, DC, United States, 20037-1701
Phone: 202 828 0850
Website: https://www.danaher.com
Employees: 58,000
Description: Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
